Literature DB >> 19757548

Population pharmacokinetics and dosing recommendations for cisplatin during intraperitoneal peroperative administration.

Hans Ehrsson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19757548     DOI： 10.2165/11317280-000000000-00000

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  14 in total

1.  Oxaliplatin degradation in the presence of important biological sulphur-containing compounds and plasma ultrafiltrate.

Authors:  Elin Jerremalm; Inger Wallin; Jeffrey Yachnin; Hans Ehrsson
Journal:  Eur J Pharm Sci       Date:  2006-04-18       Impact factor: 4.384

2.  Pharmacokinetics of cisplatin and its monohydrated complex in humans.

Authors:  A Andersson; J Fagerberg; R Lewensohn; H Ehrsson
Journal:  J Pharm Sci       Date:  1996-08       Impact factor: 3.534

3.  Disposition of unchanged cisplatin in patients with ovarian cancer.

Authors:  P A Reece; I Stafford; M Davy; S Freeman
Journal:  Clin Pharmacol Ther       Date:  1987-09       Impact factor: 6.875

4.  Phase I trial of a cisplatin-albumin complex for the treatment of cancer of the head and neck.

Authors:  J D Holding; W E Lindup; C van Laer; G C Vreeburg; V Schilling; J A Wilson; P M Stell
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

5.  Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion.

Authors:  J J Gullo; C L Litterst; P J Maguire; B I Sikic; D F Hoth; P V Woolley
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

6.  Population pharmacokinetics and dosing recommendations for cisplatin during intraperitoneal peroperative administration: development of a limited sampling strategy for toxicity risk assessment.

Authors:  Bernard Royer; Vincent Jullien; Emmanuel Guardiola; Bruno Heyd; Bruno Chauffert; Jean-Pierre Kantelip; Xavier Pivot
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.

Authors:  Miranda Verschraagen; Epie Boven; Rita Ruijter; Kasper van der Born; Johannes Berkhof; Frederick H Hausheer; Wim J F van der Vijgh
Journal:  Clin Pharmacol Ther       Date:  2003-08       Impact factor: 6.875

8.  Ototoxicity, nephrotoxicity and pharmacokinetics of cisplatin and its monohydrated complex in the guinea pig.

Authors:  Andreas Ekborn; Annika Lindberg; Göran Laurell; Inger Wallin; Staffan Eksborg; Hans Ehrsson
Journal:  Cancer Chemother Pharmacol       Date:  2002-11-02       Impact factor: 3.333

9.  Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer.

Authors:  Bernard Royer; Delphine Delroeux; Emmanuel Guardiola; Marielle Combe; Guillaume Hoizey; Damien Montange; Jean-Pierre Kantelip; Bruno Chauffert; Bruno Heyd; Xavier Pivot
Journal:  Cancer Chemother Pharmacol       Date:  2007-05-15       Impact factor: 3.333

10.  Antitumor activity and toxicity of serum protein-bound platinum formed from cisplatin.

Authors:  K Takahashi; T Seki; K Nishikawa; S Minamide; M Iwabuchi; M Ono; S Nagamine; H Horinishi
Journal:  Jpn J Cancer Res       Date:  1985-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.